Introduction
Pharmacological treatments that have been tested in upper gastrointestinal haemorrhage, such as antacids, histamine H2 receptor antagonists, and fibrinolytic inhibitors, have theoretical appeal. Candidate drugs are cheap and comparatively safe and if they proved effective they could be given to most patients with this condition, including the many who are not looked after by specialists. The efficacy of drug treatment, however, has not been adequately evaluated.' Survival is the most important measure of the success of management in upper gastrointestinal haemorrhage. In contrast with the extensive evaluation of ,3 adrenoceptor blockade or fibrinolysis after myocardial infarction,23 the trials of drug treatment in upper gastrointestinal haemorrhage have individually been too small to assess the effects on mortality.
This failure to test rigorously the candidate medical treatments for upper gastrointestinal haemorrhage is disappointing. Clinical trials are fairly straightforward, as most deaths occur within a week or two of the initial bleed and any benefits will be apparent after a short course oftreatment. In the absence ofdefinitive studies meta-analysis, which reviews critically the available clinical trials, assesses the homogeneity of any treatment effects, and pools the data to obtain an overall measure of benefit, may be valuable. 4 Colfins and Langman have reported a meta-analysis of randomised controlled trials of histamine H2 antagonists in upper gastrointestinal haemorrhage, which showed that treatment was associated with a modest reduction in the frequency of rebleeding, need for operation, and mortality and that benefit was most pronounced in patients bleeding from gastric ulcers. 5 The antifibrinolytic drug tranexamic acid was first tested in a randomised clinical trial for upper gastrointestinal haemorrhage in 1973. 6 Despite early claims of benefit,6' the drug does not appear to be widely used. For instance, the extensive survey of upper gastrointestinal haemorrhage published by the American Society for Gastrointestinal Endoscopy in 1982, which included a review of drug treatments employed by gastroenterologists in the United States, made no mention of fibrinolytic inhibitors. 8 It was uncertainty about the role offibrinolytic inhibitors that prompted this study.
The specific purpose of this study was to review and combine the results of all valid randomised controlled clinical trials in order to obtain an overall measure of the possible benefits of the use offibrinolytic inhibitors in terms of reduced rates of rebleeding, emergency surgery, and death in patients admitted to II7 Two case series were uncontrolled."4 One paper was an account of a trial in German, which was subsequently fully reported in English.92 A "controlled" clinical trial of tranexamic acid was excluded, as patients were apparently not randomly assigned to treatment.'6 A randomised placebo controlled trial of a "haemostatic solution" containing aminocaproic acid was excluded, as the mixture contained other possibly active compounds (thrombin, atropine, noradrenaline). '7 In all, six reports described the outcome in a total of 1212 patients admitted to hospital with a primary diagnosis of upper gastrointestinal haemorrhage who entered randomised placebo controlled trials of tranexamic acid.67~" ' 1 The reports of three trials did not describe the outcomes in subjects who were withdrawn after randomisation.9 1' 'In response to a request authors provided further information on 55 subjects entered in two of these trials'0 13 (D Bergqvist, personal communication; S B Eriksson, personal communication). Further details of the third trial could not be obtained. Table I gives the details of patients at entry to the six trials. In one trial most patients had bled from lesions in the stomach and duodenum. '3 In the other studies patients bleeding from oesophageal sites were included. The sex and age distributions of patients differed little except for the trial of Biggs et al, which included a larger proportion of young subjects.' There were differences in the clinical condition of patients at entry. Two trials restricted entry to subjects who had signs of an unstable circulation.9 '°In the other trials 11-23% of patients had signs of haemodynamic upset, generally defined in terms of the need for urgent resuscitation, an estimated blood loss of over 1 litre, pulse rate or blood pressure changes present on admission, or a fall in the haemoglobin concentration of more than 30 g/l in the first two days.
COMPARABILITY OF PATIENTS AT ENTRY
TREATMENT REGIMENS All patients were assigned randomly to treatment with tranexamic acid or identical placebo (table II) . In four studies tranexamic acid was initially given intravenously in a dose of [3] [4] [5] [6] g/day in divided doses followed by [3] [4] [5] [6] g/day by mouth for a further three to five days.79 ''3 In the other two studies tranexamic acid was given by mouth from the start, in one trial for two days in a dose of 12 g/day and in the other for seven days in a dose of 4-5 g/day.6
TRIAL END POINTS
The trial reports, supplemented by information provided by two authors (Bergqvist and Eriksson, personal communications), provided enough detail to assess the impact of treatment on the rate of continued or recurrent haemorrhage, the need for emergency For each trial the outcomes of the intervention were expressed as the ratios of the odds of the events (rebleeding, operation, or death) in patients assigned to tranexamic acid to the odds of these events in patients assigned to placebo. 95% Confidence intervals for the individual odds ratios were calculated by an exact method.'8 We used two techniques for pooling the data. The method of Peto,'9 which is a modified Mantel-Haenszel procedure, has been widely used and was employed by Collins and Langman in their metaanalysis of the trials of histamine H2 receptor antagonists in upper gastrointestinal haemorrhage.5 The technique assumes a constant effect across studies, the only variation in the observed effects being due to sampling error, and provides an overall outcome measure, the pooled odds ratio, and a separate test for heterogeneity of outcome. If there is heterogeneity in the treatment effects across the trials the MantelHaenszel method of obtaining a summary odds ratio may not be appropriate.
An alternative approach based on the random effects model has been proposed by DerSimonian and Laird.20 With this model the observed treatment effect for each study is partitioned into two components-the "true" treatment effect and sampling error. The true treatment effect for a study will depend on several factors, such as the selection of patients, design and conduct, and definition of outcomes. This effect can be thought of as a composite of the mean effect for the population of possible studies that could be conducted (from which the studies being included in the meta-analysis were sampled) and the deviation of the study's true effect from the population mean. If there is no heterogeneity across the studies all the deviations will be zero. The variance of the deviation terms is a measure of the heterogeneity in the treatment effects which may be incorporated into the estimate of the overall treatment effect.
An adaptation of the procedure proposed by DerSimonian and Laird to estimate the overall treatment effect, and to test for heterogeneity, was used with the logarithm of the odds ratio as the effect measure. An estimate of the pooled odds ratio was obtained by exponentiating the logarithm of the pooled odds ratio. When the treatment effects are constant across studies the estimate of the weighted odds ratio is equivalent to that proposed by Woolf.2' A measure of any heterogeneity is incorporated into the weights used in the calculation of the overall odds ratio. A test of significance was performed by comparing the Z statistic, calculated as the logarithm of the estimated odds ratio divided by its standard error (SE), with the standard normal distribution. An approximate 95% confidence interval was obtained by taking exponentials of the confidence limits calculated from the log of the estimated odds ratio and 1-96 times its SE.
Results Table III shows the outcome measures in the individual trials. The analyses include information on 55 patients withdrawn after randomisation and omitted from the original trial reports, and in all but one study they represent analyses by intention to treat. Most of the individual odds ratios were less than one, indicating possible benefit from tranexamic acid. Nevertheless, in 13 of the 17 individual trial outcomes the 95% confidence intervals included unity.
With the method of Peto'9 the pooled analyses suggested that treatment with tranexamic acid resulted in roughly a 20% reduction (estimated pooled odds ratio 0 80) in the incidence of rebleeding, a 30% reduction (estimated pooled odds ratio 0 72) in the need for emergency surgery, and a 40% reduction (estimated pooled odds ratio 0 60) in mortality (table  IV) . The reductions in operation rate and mortality achieved conventional levels of significance (p<005). Heterogeneity in outcomes was evident in the cases of rebleeding and operation rates. Because of this the data were reworked by using the random effects model. The results indicated roughly a 30% reduction in the occurrence of rebleeding with tranexamic acid and roughly 40% reductions in operation rate and mortality (table IV) . As with Peto's method, the reduction in mortality was significant. The estimated effects of tranexamic acid on mortality were homogeneous when tested by both methods, and predictably the pooled odds ratio with its confidence interval was unchanged when recalculated by the method of DerSimonian and Laird. 20 Reanalysis of the data from those patients who completed their treatments (573 tranexamic acid, 567 placebo) produced similar trends to those seen in the analyses by intention to treat. By the method of Peto'9 the estimated odds ratios (95% confidence intervals) were: for rebleeding 075 (0-56 to 100; p=005), for operation 0-69 (0A49 to 0-96; p=0027), and for mortality 0 54 (0-34 to 0 85; p=0008). By the method of DerSimonian and Laird20 the estimated odds ratios were: for rebleeding 0-69 (046 to 1O00; p=007), for operation 053 (0-24 to 1b20; p=0O12), and for mortality 0 54 (0 33 to 0-88; p=001).
Other evidence of benefit-In two trials the average total transfusion requirement was significantly reduced in patients given the active treatment,613 and in two trials the transfusion requirement was significantly lower on particular days after admission to hospital.79 One trial found no difference and the other a slight increase in the units of blood received by treated patients.'0 " Because of inconsistencies in the reporting of results these data were not included in the meta-analyses. Side effects oftreatment-Adverse events reported in patients given tranexamic acid were one cerebral infarct, two myocardial infarcts, two episodes of pulmonary embolism, one deep vein thrombosis, and five cases of superficial thrombophlebitis. By comparison two cerebral infarcts and two episodes of thrombophlebitis were reported in patients given placebo. One event possibly associated with tranexamic acid was reported as fatal. The patient, a man, had a transient cerebral ischaemic attack followed by a fatal stroke five days after discharge from hospital. He also had polycythaemia requiring venesection.
Discussion
These results indicate that tranexamic acid given for upper gastrointestinal haemorrhage may result in worthwhile reductions in the frequency of continued or recurrent haemorrhage, the need for urgent surgery, and mortality. A benefit of treatment was apparent when the data were analysed on the basis ofintention to treat and remained when the analyses were confined to patients who completed their treatment. Though the total number of subjects included in this meta-analysis was less than half that included in the study by Collins and Langman evaluating histamine H2 receptor antagonists in upper gastrointestinal haemorrhage, the estimated treatment effects appeared to be similar. 5 Tranexamic acid has a plausible mode of action in upper gastrointestinal haemorrhage. It is an inhibitor of plasminogen, and plasminogen activators have been found in the gastric and duodenal mucosa.22 High activities of plasmin have been detected in the gastric venous effluent of patients with peptic ulcers.23 Aminocaproic acid, which has a similar action to tranexamic acid, inhibits the release of plasmin.24 In addition, tranexamic acid has been shown to inhibit the fibrinolytic action of pepsin.25 This effect is independent of changes in pH, which may have particular relevance for patients who are critically ill and whose gastric contents may remain acidic despite treatment with histamine H2 receptor antagonists. 26 In contrast with H2 antagonists, which are given to most patients after an episode of gastrointestinal bleeding, tranexamic acid appears to be used rarely by gastroenterologists.8 There are several possible explanations. Histamine H2 receptor antagonists are prescribed widely after upper gastrointestinal haemorrhage, probably because they heal ulcerated lesions rather than because of faith in their modest effects in reducing the rate of recurrent haemorrhage and death. In contrast, tranexamic acid has no proved ulcer healing effect and is not given unless it is thought likely to improve the short term outlook after an episode of bleeding. Probably the lack of popularity of tranexamic acid for upper gastrointestinal haemorrhage is due to a widespread belief that it is inefficacious. Of the six trials included in this meta-analysis, only one was large enough to detect a reduction in mortality. In the study by Barer et al mortality was reduced by over 50% but there were no parallel reductions in the rates of rebleeding and need for operative intervention." This lack of internal consistency may have contributed to doubts that have been expressed about the benefits of tranexamic acid.2728 As our analyses show, treatment may reduce the likelihood of repeated haemorrhage and the need for surgery. The trends, however, were not as strong as in the case of mortality.
Another factor which may have limited the use of tranexamic acid is concern about toxicity. In subarachnoid haemorrhage the benefits of the drug in terms of reduced mortality from rebleeding were offset by a larger number of deaths from cerebral infarction in the treated group. 29 Though reporting of adverse events such as thrombosis may have been incomplete in the trials of tranexamic acid for upper gastrointestinal haemorrhage, our analyses of mortality included all deaths occurring during that hospital admission, irrespective of cause, and treatment was associated with an overall benefit.
Our analyses highlighted some heterogeneity in the outcomes of the trials of tranexamic acid, particularly in the case ofoperation rates. There are several possible reasons. There was considerable variation in the case mix included in the trials, in particular the proportion of patients who had clinical shock at entry. The trials were conducted in three countries and treatment regimens varied, tranexamic acid being given intravenously or by mouth in different doses. There were also differences in the definitions of rebleeding and the criteria for surgical intervention. There might have been less heterogeneity had we been able to analyse the outcomes in the different diagnostic subgroups. Because of the greater statistical power of Collins and Langman's meta-analysis of the trials of histamine H2 receptor antagonists they were able to examine subsets and showed significant reductions in the rates of rebleeding, operation, and death in patients bleeding from gastric ulcers but not in those bleeding from duodenal ulcers.' The effects were homogeneous in the group with gastric ulcer.5 Because of smaller numbers and incomplete reporting of some trials we could not analyse the results from diagnostic subsets.
The extent to which heterogeneity should influence interpretation of the findings of meta-analyses is controversial. In some studies data showing heterogeneity in outcome would not have biased the meta-analysis in favour of active treatment. The likelihood of data extraction bias is small, as the endpoint frequencies used in the analysis were those published by the authors, in some cases supplemented by data on patients withdrawn after randomisation. Though data were not extracted blind in respect of the treatment assigned (the ideal suggested by Sacks et all), editing did not take place before their inclusion in the analysis.
Publication bias-that is, the preferential publication of positive studies -remains the main threat to the validity of this or any other meta-analysis. Using the example of ovarian cancer, Simes has shown that a pooled analysis of the results of trials registered with an international data bank provided a more conservative estimate of the benefits of combination chemotherapy than a pooled analysis of only those studies which had been published.3' In a recent review Begg and Berlin emphasised the importance of considering publication bias when interpreting the findings of meta-analyses."2 They reviewed several contributory factors including sample size, which is likely to be important in the case of drug trials in gastrointestinal bleeding.
Whereas large trials possibly comprising thousands of patients will provide precise estimates of size of effect and are highly likely to be published even if they are negative, small negative trials are less likely to be submitted or accepted for publication. In this regard it is worrying that trials of new treatments for gastrointestinal bleeding have, in general, been small. For instance, the average number of patients assigned to treatment with tranexamic acid was 105, and in the meta-analysis of the trials of histamine H2 receptor antagonists in upper gastrointestinal haemorrhage the average number of patients assigned to active treatment was only 50.5 Given the requirement for sample sizes in the thousands in order to detect small but clinically important reductions in the mortality from upper gastrointestinal haemorrhage, it is easy to see how a number of small negative trials could be regarded as inadequate by referees or journal editors and remain unpublished. The magnitude of this type of publication bias will depend on how the results of individual trials are perceived. Given the small size of the effects noted in the individual trials of tranexamic acid, these were interpreted in a surprisingly positive way by the authors, some of whom were influenced by other factors, particularly an apparent reduction in transfusion requirements in treated patients. It is very difficult for us to make adjustments for these unknown biases, and the results ofthis analysis must therefore be applied with caution.
The evidence presented here raises important issues regarding the optimum management ofpatients at high risk after admission to hospital with an episode of acute upper gastrointestinal haemorrhage. Tranexamic acid may be of benefit and treatment is cheap. The cost of a week's treatment in an Australian public hospital is around $A 40. It is interesting to speculate whether there might be an additional benefit if tranexamic acid was used in combination with a histamine H2 antagonist, antacids, or a proton pump inhibitor. Theoretically, there may be advantages in adding a plasminogen inactivator to treatment aimed at raising the intragastric pH to a level at which pepsin is completely inactivated.33 An additive effect of clinical importance could be confirmed only by well controlled randomised trials of adequate size and factorial design. 34 Attention has already been drawn to the urgent need for large randomised clinical trials in upper gastrointestinal haemorrhage, which, as in trials in myocardial infarction, should have survival as their main end point.' Our study reinforces this call and provides estimates of size of effect, which would be valuable in the planning of definitive trials.
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